Novo Nordisk (NVO) is launching its Wegovy pill in the U.S. on Monday, offering 1.5 milligram, mg, and 4 mg doses at $149 per month for self-paying patients, Jacob Gronholt-Pedersen and Bhanvi Satija of Reuters reports. A 9 mg and 25 mg dose will also be available, which will be priced at $299 for a month’s supply. Additionally, the 4 mg dose will rise to $199 on April 15.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Stock Jumps as it Battles Eli Lilly for Market Share with $149 Wegovy Pill Launch
- Moderately bullish activity in Novo Nordisk with shares up 2.31%
- Pfizer (PFE) Tops List as Drugmakers Plan Price Hike on 350 Medications
- Midday Fly By: SoftBank buying DigitalBridge, Verisk drops AccuLynx deal
- Novo cuts listing prices for Wegovy in some Chinese provinces, Bloomberg says